Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

被引：28

作者：

Compston J.E. ^{[1
]}

机构：

[1] University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Box 157

来源：

Current Rheumatology Reports | 2007年 / 9卷 / 1期

关键词：

Bone Mineral Density; Vertebral Fracture; Alendronate; Risedronate; Ibandronate;

D O I：

10.1007/s11926-007-0026-x

中图分类号：

学科分类号：

摘要：

Glucocorticoid-induced osteoporosis is a common but still relatively neglected problem, with a low level of awareness among primary and secondary care physicians. Fractures appear early after initiation of treatment, and effective prophylaxis requires primary prevention in those at high risk of fracture. Bisphosphonates are the treatment of choice, and calcium and vitamin D supplements are also indicated in the majority of individuals. Organized care programs together with the use of evidence-based guidelines have the potential to improve significantly the management of this serious complication of glucocorticoid therapy. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：78 / 84

页数：6

共 45 条

[1]

van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Use of oral corticosteroids in the United Kingdom, QJM, 93, pp. 105-111, (2000)

[2]

Hooyman J.R., Melton L.J., Nelson A.M., Et al., Fractures after rheumatoid arthritis. A population-based study, Arthritis Rheum, 27, pp. 1353-1361, (1984)

[3]

van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Use of oral corticosteroids and risk of fractures, J Bone Miner Res, 15, pp. 993-1000, (2000)

[4]

Steinbuch M., Youket T.E., Cohen S., Oral glucocorticoid use is associated with an increased risk of fracture, Osteoporos Int, 15, pp. 323-328, (2004)

[5]

Mazziotti G., Angeli A., Bilezikian J.P., Et al., Glucocorticoid-induced osteoporosis: An update, Trends Endocrinol Metab, 17, pp. 144-149, (2006)

[6]

van Staa T.P., Leufkens H.G., Abenhaim L., Et al., Oral cortico-steroids and fracture risk: Relationship to daily and cumulative doses, Rheumatology (Oxford), 39, pp. 1383-1389, (2000)

[7]

van Staa T.P., Dennison E.M., Leufkens H.G., Cooper C., Epidemiology of fractures in England and Wales, Bone, 29, pp. 517-522, (2001)

[8]

Ip M., Lam K., Yam L., Et al., Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids, Chest, 105, pp. 1722-1727, (1994)

[9]

Toogood J.H., Baskerville J.C., Markov A.E., Et al., Bone-mineral density and the risk of fracture in patients receiving long-term inhaled steroid-therapy for asthma, J Allergy Clin Immunol, 96, pp. 157-166, (1995)

[10]

Wong C.A., Walsh L.J., Smith C.J., Et al., Inhaled corticosteroid use and bone mineral density in patients with asthma, Lancet, 355, pp. 1399-1403, (2000)

← 1 2 3 4 5 →